CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development ...

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and ...

TENX opened at $5.80 on Friday. The firm has a market cap of $23.03 million, a price-to-earnings ratio of -1.09 and a beta of 1.88. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month ...

Reports Tenax Therapeutics (TENX) reported cash and cash equivalents of $94.9 M as of December 31 . In addition, in March 2025 the Company raised approximately $25M in gross proceeds from a ...